Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

Journal of the American College of Cardiology

Volumn 58, Issue 1, 2011, Pages 30-39

  Angiolillo, Dominick J ^a   Bernardo, Esther ^b   Zanoni, Martina ^c   Vivas, David ^b   Capranzano, Piera ^a   Malerba, Giovanni ^c   Capodanno, Davide ^a   Prandini, Paola ^c   Pasquali, Alessandra ^c   Trabetti, Elisabetta ^c   Sabaté, Manel ^b   Jimenez Quevedo, Pilar ^b   Ferreiro, Jose L ^a   Ueno, Masafumi ^a   Bass, Theodore A ^a   Pignatti, Pier Franco ^c   Fernandez Ortiz, Antonio ^b   MacAya, Carlos ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

antiplatelet therapy; diabetes mellitus; gene; platelet function

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; INSULIN RECEPTOR SUBSTRATE 1;

ADULT; AGED; ALLELE; ARTICLE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE FUNCTION; THROMBOCYTE REACTIVITY;

ALLELES; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; ODDS RATIO; PHENOTYPE; RISK; TREATMENT OUTCOME;

EID: 79959513241     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.02.040     Document Type: Article

References (51)

1. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/nonST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 50 2007 e1 e157
2. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) J Am Coll Cardiol 54 2009 2205 2241
3. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516 (Pubitemid 46517957)
4. D.J. Angiolillo Variability in responsiveness to oral antiplatelet therapy Am J Cardiol 103 2009 27A 34A
5. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 54 2005 2430 2435 (Pubitemid 41134272)
6. D.J. Angiolillo, E. Bernardo, and C. Ramirez Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment J Am Coll Cardiol 48 2006 298 304 (Pubitemid 44026661)
7. T. Geisler, N. Anders, and M. Paterok Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation Diabetes Care 30 2007 372 374 (Pubitemid 46198349)
8. D.J. Angiolillo Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions Diabetes Care 32 2009 531 540
9. D.J. Angiolillo, E. Bernardo, and M. Sabaté Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547 (Pubitemid 47532327)
10. F. Marin, R. González-Conejero, P. Capranzano, T.A. Bass, V. Roldan, and D.J. Angiolillo Pharmacogenetics in cardiovascular antithrombotic therapy J Am Coll Cardiol 54 2009 1041 1057
11. I.A. Ferreira, K.L. Eybrechts, A.I. Mocking, C. Kroner, and J.W. Akkerman IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi J Biol Chem 279 2004 3254 3264 (Pubitemid 38140559)
12. I.A. Ferreira, A.I. Mocking, and M.A. Feijge Platelet inhibition by insulin is absent in type 2 diabetes mellitus Arterioscler Thromb Vasc Biol 26 2006 417 422 (Pubitemid 43732209)
13. G. Sesti, M. Federici, M.L. Hribal, D. Lauro, P. Sbraccia, and R. Lauro Defects of the insulin receptor substrate (IRS) system in human metabolic disorders FASEB J 15 2001 2099 2111 (Pubitemid 32927927)
14. M.G. Baroni, M.P. D'Andrea, and A. Montali A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease Arterioscler Thromb Vasc Biol 19 1999 2975 2980 (Pubitemid 30029827)
15. K.G. Alberti, P.Z. Zimmet WHO Consultation Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation Diabet Med 15 1998 539 553 (Pubitemid 28319935)
16. C.P. Cannon, A. Battler, R.G. Brindis American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee) American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes J Am Coll Cardiol 38 2001 2114 2130
17. T. Cuisset, C. Frere, and J. Quilici High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
18. G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol 52 2008 1128 1133
19. E. Halperin, G. Kimmel, and R. Shamir Tag SNP selection in genotype data for maximizing SNP prediction accuracy Bioinformatics 21 2005 i195 i203
20. O. Davidovich, G. Kimmel, and R. Shamir GEVALT: an integrated software tool for genotype analysis BMC Bioinformatics 8 2007 36
21. GEnotype Visualization and ALgorithmic Tool http://acgt.cs.tau.ac.il/ gevalt/ Accessed April 2011
22. R.C. Lewontin On measures of gametic disequilibrium Genetics 120 1988 849 852 (Pubitemid 18260517)
23. J.C. Barrett, B. Fry, J. Maller, and M.J. Daly Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 2005 263 265 (Pubitemid 40202029)
24. N.J. Breet, J.W. van Werkum, and H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
25. S. Lake, H. Lyon, E. Silverman, S. Weiss, N. Laird, and D. Schaid Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous Human Hered 55 2003 56 65 (Pubitemid 36928747)
26. P.M. Ridker, J.E. Buring, N. Rifai, and N.R. Cook Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 297 2007 611 619
27. D.J. Angiolillo, A. Fernández-Ortiz, and E. Bernardo Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 26 2006 1895 1900 (Pubitemid 44305347)
28. J.S. Hulot, A. Bura, and E. Villard Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247 (Pubitemid 44497506)
29. J.T. Brandt, S.L. Close, and S.J. Iturria Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436 (Pubitemid 350154353)
30. D. Trenk, W. Hochholzer, and M.F. Fromm Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934 (Pubitemid 351636443)
31. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome P450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
32. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
33. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
34. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
35. L. Wallentin, S. James, R.F. Storey PLATO investigators Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
36. J.I. Osende, J.J. Badimon, and V. Fuster Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control J Am Coll Cardiol 38 2001 1307 1312 (Pubitemid 33033003)
37. M. Ueno, J.L. Ferreiro, and S.D. Tomasello Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease Thromb Haemost 105 2011 730 732
38. D.L. Yee, C.W. Sun, A.L. Bergeron, J.F. Dong, and P.F. Bray Aggregometry detects platelet hyperreactivity in healthy individuals Blood 106 2005 2723 2729 (Pubitemid 41510746)
39. A.M. Gori, R. Marcucci, and R. Paniccia Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function Thromb Haemost 100 2008 1136 1145
40. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention Am J Cardiol 97 2006 38 43 (Pubitemid 41828120)
41. J. DiChiara, K.P. Bliden, and U.S. Tantry The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 56 2007 3014 3019 (Pubitemid 350223637)
42. D. Capodanno, A. Patel, and K. Dharmashankar Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease Circ Cardiovasc Interv 4 2011 180 187
43. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease Diabetes 55 2006 780 784 (Pubitemid 43343236)
44. D.J. Angiolillo, S.B. Shoemaker, and B. Desai Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716 (Pubitemid 46294761)
45. D.J. Angiolillo, P. Capranzano, and S. Goto A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur Heart J 29 2008 2202 2211
46. D.J. Angiolillo, D.L. Bhatt, P.A. Gurbel, and L.K. Jennings Advances in antiplatelet therapy: agents in clinical development Am J Cardiol 103 2009 40A 51A
47. D.J. Angiolillo, J.J. Badimon, and J.F. Saucedo A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial Eur Heart J 32 2011 838 846
48. S.D. Wiviott, E. Braunwald, D.J. Angiolillo TRITONTIMI 38 Investigators Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrelThrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
49. J.L. Ferreiro, and D.J. Angiolillo Diabetes and antiplatelet therapy in acute coronary syndrome Circulation 123 2011 798 813
50. L. Bonello, U.S. Tantry, R. Marcucci Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP J Am Coll Cardiol 56 2010 919 933
51. J.C. Florez, M. Sjgren, and C.M. Agapakis Association testing of common variants in the insulin receptor substrate-1 gene (IRS1) with type 2 diabetes Diabetologia 50 2007 1209 1217 (Pubitemid 46701562)